Tradestie Institutional Equity Comparison Engine

XOMA vs URGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XOMA Overall Edge

XOMA Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to XOMA Royalty Corporation Common Stock (XOMA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while URGN counters with relative strength in Valuation. Fundamentally, XOMA trades at 21.5x Forward P/E with -3.9% operating margin (-22.6% YoY revenue) versus URGN at 10.2x Forward P/E and -12.4% operating margin (+223.9% YoY). In options structure, XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against URGN sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner URGN
XOMA 21.5x vs URGN 10.2x Fwd P/E
Growth & Margin Winner XOMA
Op Margin -3.9% vs -12.4% ยท YoY -22.6% vs +223.9%
Momentum & Technical Winner XOMA
1Y +44.0% vs +17.1% ยท 52W Pos 78% vs 34%
Options & Structure Winner XOMA
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (10th %ile IV)
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
URGN NASDAQ
UroGen Pharma Ltd. Ordinary Shares
Pharmaceutical Preparations
$28.01
+6.99% 1D
Market Cap $1.3B
1M Return -18.95%
1Y Return +17.1%
Forward P/E 10.2x
Unified AI Score
61.5 / 100 BUY
Tech 70.0 Fund 66.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XOMA +43.98% URGN +17.1% Spread: +40.58 pp (URGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XOMA TTM Op. Margin: -3.9% URGN TTM Op. Margin: -12.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs URGN. Trailing 12-month operating profitability (XOMA -3.9% vs URGN -12.4%) and valuation multiples (XOMA 21.5x vs URGN 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XOMA (5) vs URGN (5)
Institutional Metric XOMA URGN Criterion Row Winner
Market Capitalization Scale $781.8M $1.3B Larger Scale URGN
Trailing P/E Ratio Valuation 28.2x 12.9x Lower Multiple URGN
Forward P/E Ratio Valuation 21.5x 10.2x Lower Multiple URGN
Revenue Growth (YoY) Growth -22.6% +223.9% Higher Growth URGN
Operating Margin (TTM) Profitability -3.9% -12.4% Higher Margin XOMA
Net Profit Margin Profitability 69.6% -26.3% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency 34.2% -1481.3% Higher ROE XOMA
52-Week Range Position Momentum 78% ($22โ€“$45) 34% ($16โ€“$51) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 37% Vol 1.32ฮฒ ยท 85% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 55.8 / 100 (HOLD) 61.5 / 100 (BUY) Higher Composite URGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XOMA vs URGN Buy Guide
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
URGN BREAKDOWN
96d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live URGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XOMA nor URGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.